

ANTIOXIDANTS AND OTHER NUTRIENTS DO NOT INTERFERE WITH CHEMOTHERAPY OR RADIATION THERAPY AND CAN INCREASE KILL AND INCREASE SURVIVAL, PART 1

Charles B. Simone II, MD; Nicole L. Simone, MD; Victoria Simone, RN; Charles B. Simone, MD

Purpose • Some in the oncology community contend that patients undergoing chemotherapy and/or radiation therapy should not use food supplement antioxidants and other nutrients. Oncologists at an influential oncology institution contended that antioxidants interfere with radiation and some chemotherapies because those modalities kill by generating free radicals that are neutralized by antioxidants, and that folic acid interferes with methotrexate. This is despite the common use of amifostine and dexrazoxane, 2 prescription antioxidants, during chemotherapy and/or radiation therapy.

Design • To assess all evidence concerning antioxidant and other nutrients used concomitantly with chemotherapy and/or radiation therapy, the MEDLINE® and CANCELIT® databases were searched from 1965 to November 2003 using the words *vitamins*, *antioxidants*, *chemotherapy*, and *radiation therapy*. Bibliographies of articles were searched. All studies reporting concomitant nutrient use with chemotherapy and/or radiation

therapy (280 peer-reviewed articles including 62 in vitro and 218 in vivo) were indiscriminately included.

Results • Fifty human clinical randomized or observational trials have been conducted, involving 8,521 patients using beta-carotene; vitamins A, C, and E; selenium; cysteine; B vitamins; vitamin D₃; vitamin K₃; and glutathione as single agents or in combination.

Conclusions • Since the 1970s, 280 peer-reviewed in vitro and in vivo studies, including 50 human studies involving 8,521 patients, 5,081 of whom were given nutrients, have consistently shown that non-prescription antioxidants and other nutrients do not interfere with therapeutic modalities for cancer. Furthermore, they enhance the killing of therapeutic modalities for cancer, decrease their side effects, and protect normal tissue. In 15 human studies, 3,738 patients who took non-prescription antioxidants and other nutrients actually had increased survival. (*Altern Ther Health Med.* 2007;13(1):22-28.)

Charles B. Simone II, MD, and Nicole L. Simone, MD, are consulting physicians, Victoria Simone, RN, is a research nurse, and Charles B. Simone, MD, is a consulting physician and medical director, all at the Simone Protective Cancer Institute in Lawrenceville, NJ.

Editor's note: The following is part 1 of a 2-part article. Part 2 will appear in the March/April 2007 issue of Alternative Therapies in Health and Medicine.

Two of every 5 Americans will develop cancer, and the incidence of most cancers has increased annually since 1930.¹⁻⁵ In addition, since 1930, despite the use of radiation therapy, chemotherapy, immunotherapy, and improved surgical and diagnostic techniques, there has been limited improvement in cancer survival

rates for most adult cancers.¹⁻⁵ Chemotherapy and radiation therapy, however, continue to have a large role in cancer treatment but produce great morbidity. Two prescription medicines, amifostine and dexrazoxane, both antioxidants, reduce cancer therapy side effects without interfering with antitumor killing. Amifostine (WR-2721) is an antioxidant analog of cysteamine that was discovered by the armed forces at Walter Reed Army Medical Center, Washington, DC, and became the first antioxidant agent to be approved by international regulatory agencies.⁶ According to 29 studies, amifostine reduces side effects and increases response rates of chemotherapy and radiation therapy without interfering with their antitumor killing activity.⁶⁻¹⁸ Twenty-one studies indicate that dexrazoxane (ICRF-187) protects the heart from adriamycin toxicity without interfering with the antitumor effect¹⁹⁻²² by chelating iron that would otherwise form free radicals.²³⁻²⁶

Despite the common use of amifostine and dexrazoxane, and in direct opposition to clear scientific findings since the 1970s,

many patients have been told not to use food supplement antioxidants and other nutrients while undergoing chemotherapy and/or radiation therapy because there is an erroneous but seemingly logical belief that antioxidants interfere with radiation and some chemotherapies because those modalities kill by generating free radicals that are neutralized by antioxidants, and another erroneous belief that folic acid interferes with methotrexate.^{27,32}

In an article that appeared on the front page of *The New York Times* on October 26, 1997, Larry Norton, MD, of Memorial Sloan Kettering Cancer Center, New York, was quoted as saying, "Research at [Memorial Sloan Kettering] showed that large doses of vitamin C could blunt the beneficial effects of chemotherapy for breast cancer. . . . It is also known that folic acid can negate the effects of methotrexate, a drug used to treat cancer."²⁷ The research referred to was finally published almost 2 years later and demonstrated only the mechanism by which cancer cells obtain vitamin C and that more vitamin C was found in mice cancer cells compared to normal mice cells.²⁹ However, the senior author of that paper stated in a news release on the day of publication (September 15, 1999), "It's possible that taking large amounts of vitamin C could interfere with the effects of chemotherapy or even radiation therapy."³⁰ So a single interview in *The New York Times* in 1997 that was not based on published scientific work and a single research paper involving mice, along with a press release by its author in 1999, led to the erroneous notion that vitamin C interferes with chemotherapy and radiation in humans. This notion soon applied to all antioxidants as physicians, patients, the media, the American Cancer Society,^{31,32} and scores of websites took the same position without reviewing the scientific evidence.

This 2-part article presents the scientific data that antioxidants do not interfere with chemotherapy and/or radiation therapy. Furthermore, it is not folic acid that interferes with the action of methotrexate, but rather folinic acid, a prescription drug that is neither a vitamin nor an antioxidant.³³⁻³⁵ This article reviews data about vitamin A, beta-carotene, and vitamin E. Part 2 will review data about antioxidant combinations, B vitamins, vitamins D₃ and K₃, and the glutathione-selenium complex.

METHODS

MEDLINE® and CANCERLIT® searches were done using key words: vitamins, antioxidants, chemotherapy, and radiation therapy. All studies reporting food supplement nutrients used concomitantly with chemotherapy and/or radiation therapy were indiscriminately included; however, in cases in which an author had published his or her findings in multiple sources, only the most recently published paper was used as it usually contained the greatest number of patients.

BACKGROUND

Radiation and certain chemotherapies produce cellular kill by generating free radicals; antioxidants neutralize free radicals and the oxidative reactions that are caused by free radicals (Table 1).

Other nutrients are included in this review. B vitamins

TABLE 1 Agents That Generate or Neutralize Free Radicals

Generate Free Radicals	Antioxidants (Neutralize Free Radicals)
Alkylating Agents	Amifostine
Alkyl sulfonate—busulfan	Carotenoids—beta-carotene, lutein, lycopene
Ethylenimine derivative—thiotepa	Coenzyme Q10
Metal salt—cisplatin, carboplatin	Dexrazoxane
Nitrogen mustard—chlorambucil, estramustine, cyclophosphamide, ifosfamide, melphalan	Glutathione-selenium complex
Nitrosourea—carmustine	N-acetyl cysteine
Triazine—dacarbazine	Selenium
	Vitamin C
	Vitamin E
Natural Products	
Antibiotic—bleomycin, dactinomycin, daunorubicin, doxorubicin (adriamycin), idarubicin, mithramycin, mitomycin, mitoxantrone	
<i>Podophyllum</i> derivative—etoposide, teniposide	
Other —procarbazine	
Radiation —all forms	

enhance the immune system and protect normal cells from the harm of radiation and other destructive mechanisms. Glutathione peroxidase, a selenium-containing antioxidant enzyme complex, protects the cell from free-radical injury. Glutathione peroxidase is easier to measure than selenium and has the advantage of assessing only biologically active selenium. Vitamin A and retinoids have anti-cancer effects, repair normal cells, and modulate the growth and differentiation of malignant cells. Vitamin D₃ inhibits cancer cell proliferation and replication, induces differentiation of leukemia cells, inhibits the oncogene *c-myc*, and enhances the immune system. Vitamin K₃ (menadiolone) inhibits cell growth, cell proliferation, DNA synthesis, and the cell cycle. Vitamin K₃ acts on apoptosis through expression of *c-myc* and *c-fos* proto-oncogenes and lowers intracellular pools of reduced glutathione.

Effects of Chemotherapy and Radiation Therapy on Serum Nutrient Levels

Cancer patients suffer from caloric and nutritional malnutrition and have vitamin deficiencies, particularly of folic acid, vitamin C, pyridoxine, and other nutrients because of poor nutrition and treatment.³⁸ Chemotherapy and radiation therapy reduce serum levels of antioxidant vitamins and minerals due to lipid peroxidation and thus produce higher levels of oxidative stress.³⁶⁻⁶⁶ Iron could be the intermediate cause of this oxidative stress.²⁰⁻²³ Therefore, supplemental iron should not be recommended to cancer patients who have anemia unless it is an iron-deficiency anemia.

Early Studies

Five early studies showed that N-acetyl cysteine, an antioxidant, protects the heart from the cardiac toxicity of adriamycin without interfering with the tumor-killing capability of adriamycin.⁶⁷ Seven cellular studies,⁶⁸⁻⁷⁰ 22 animal studies,⁷¹⁻⁷⁵ and human studies⁷⁶⁻⁷⁸ have demonstrated that vitamins A, E, C, and K, as well as beta-carotene and selenium—as single agents or in combination—all protect against the toxicity of adriamycin and actually enhance its cancer-killing effects.

Cellular and Animal Studies

Fifty-one cellular⁷⁹⁻⁸⁸ and 81 animal studies⁸⁹⁻¹¹⁰ using nutrients that include vitamins A, B₆, B₁₂, C, D, E, and K, beta-carotene, other retinoids, selenium, or cysteine as single agents or in combination given concomitantly with chemotherapy, radiation, or combinations of these modalities show the same effect—no interference, increased protection of normal tissues, increased tumor killing, and, in some studies, increased animal survival.

Observational Versus Randomized Clinical Studies

Compared to randomized studies, observational studies are less costly, can be done more quickly, and have a broader range of patients. Observational studies provide valid information and virtually the same results as randomized studies, a finding that differs from previous conclusions.^{111,112} Furthermore, “Observational studies do not overestimate the magnitude of the effects of treatment compared with those in randomized trials on the same topic.”^{113(p1887)} In this 2-part article, we will summarize 50 human studies, 36 observational and 14 randomized, that reported concomitant nutrient use with chemotherapy and/or radiation therapy.

Review of Human Studies

Fifty human studies, involving 8,521 patients, have been conducted using single or multiple nutrients in combination with systemic treatment and/or radiation treatment and demonstrate that nutrients do not interfere with treatment. In fact, 47 of these 50 studies indicated that nutrients decrease side effects of treatment, and the other 3 studies showed no difference. In addition, many of the studies reported that nutrients produce higher response rates and higher survival rates when administered concomitantly with chemotherapy and/or radiation therapy. This part of the 2-part article reviews data about vitamin A, beta-carotene, and vitamin E.¹¹⁴⁻¹³⁰

VITAMIN A (RETINYL PALMITATE)

In a randomized study of 100 postmenopausal patients with metastatic breast carcinoma undergoing chemotherapy (cyclophosphamide, 5-fluorouracil, bleomycin, adriamycin, mitomycin), patients were given daily doses of vitamin A (350,000-500,000 IU, according to body weight). Vitamin A—which many people erroneously believe is an antioxidant—significantly increased the complete response rate, duration of response, and projected survival.¹¹⁴

In an observational study of 275 patients with head and neck cancer, patients were treated with 5-fluorouracil and cobalt-60 radiation, as well as vitamin A. Vitamin A enhanced the cellular sensitivity to irradiation, increased treatment response rate, and lowered toxic side effects.¹¹⁵

In a randomized study of 153 patients with chronic myelogenous leukemia (CML), patients were randomized to receive pulse oral busulfan with or without the daily administration of oral vitamin A (50,000 IU). Patients receiving only busulfan had a shorter survival, with a 42% greater risk of death. In addition to increasing survival, vitamin A decreased side effects and increased treatment response rate.¹¹⁶

In an observational study of 40 patients with stage IIIB or stage IV non-small cell lung cancer, patients were treated with cisplatin (120 mg/m² divided into 5 days), vindesine (3 mg/m² on days 1 and 5), 5-fluorouracil (500 mg/m² on days 1 and 5), beta-interferon (1 million IU 3 times a week), and retinyl palmitate (50,000 IU twice a day). Vitamin A produced fewer side effects, a higher response rate, and increased survival compared to historical controls.¹¹⁷

In an observational study, 23 patients with unresectable or recurrent advanced oral cavity cancer were treated with 5-fluorouracil (1,000 mg/m²) and cisplatin (20 mg/m²) for 5 days. Vitamin A (15,000 IU twice a day) was also given throughout the treatment. Vitamin A decreased side effects, increased response rate, and slightly increased survival.¹¹⁸

In an observational study of 36 patients with stage IV breast cancer, patients were treated with cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine, and prednisone every 3 weeks for 6 courses, followed by 2 courses of methotrexate, mitomycin-C, and mitoxantrone. Treatment continued with tamoxifen and vitamin A. Sixty-four percent of patients had a clinical response, 19% had stable disease, and side effects were minimal. Median overall survival was 32 months. These results compare favorably with historical controls.¹¹⁹

In an observational study of 22 patients with unresectable and/or metastatic pancreatic cancer, patients were treated with folic acid (200 mg/m²), 5-fluorouracil (370 mg/m²), epirubicin (60 mg/m²), mitomycin-C (10 mg/m²), interferon (1 million IU/m² 3 times a week), and vitamin A (50,000 IU twice a day). Response rates and survival were similar to historical controls.¹²⁰

In an observational study of 49 patients with metastatic breast cancer, 33 were treated with tamoxifen (30 mg/d), interferon (1 million IU 3 times a week), and vitamin A (15,000 IU twice a day). Sixteen patients were treated with tamoxifen (30 mg/d), interferon (3 million IU 3 times a week), and vitamin A (50,000 IU twice a day). There was no statistically significant difference in the response rate, response duration, or survival in the 2 groups treated with different dose levels of vitamin A and interferon. Compared to the Surveillance, Epidemiology, and End Results (SEER) Program data of the National Cancer Institute, however, these patients had a higher response rate and longer survival with fewer side effects.¹²¹

BETA-CAROTENE

In a randomized study of 20 patients with advanced squamous carcinoma of the mouth, patients were given 60 Gy cobalt radiation therapy in 30 fractions. The week before and after radiation, and also during the third and sixth weeks of radiation, patients were given synchronous injections of chemotherapy consisting of vincristine (2 mg), methotrexate (200 mg), and bleomycin (30 mg). Patients were randomized to receive supplemental beta-carotene (250 mg for days 1-21; 75 mg daily thereafter). No toxic side effects of beta-carotene were observed. Patients who received supplemental beta-carotene had less severe acute mucosal reactions.¹²²

In an observational study of 15 patients treated with chemotherapy for various advanced cancers, patients were given chemotherapy/radiation therapy and beta-carotene. Beta-carotene decreased side effects and allowed for a longer than expected disease-free interval in all surviving patients.¹²³

VITAMIN E (ALPHA-TOCOPHEROL)

In an observational study of 66 patients with transfusion-dependent myelodysplastic syndrome, patients received either high-dose 13-cis-retinoic acid only or high-dose 13-cis-retinoic acid with alpha-tocopherol. Patients who received alpha-tocopherol had decreased measures of skin and constitutional toxicities and were able to achieve longer treatment continuation with 13-cis-retinoic acid. As a result, fewer of these patients experienced progression to acute leukemia (28%) when compared to patients who received 13-cis-retinoic acid only (60%). A 2-fold increase in median survival also was observed in the group treated with vitamin E.¹²⁴

In an observational study of 39 patients with head and neck, skin, or lung cancer, study participants were treated with high-dose 13-cis-retinoic acid (100 mg/m² orally per day) and alpha-tocopherol administered in escalating dose schedules of 800, 1200, 1600, and 2000 IU per day for each subsequent 4-week treatment cycle. Over a 3-month period, patients experienced fewer grade 2 and grade 3 toxicities from high-dose 13-cis-retinoic acid without altering its plasma concentration.¹²⁵

In an observational study of 17 patients with myelodysplasia, patients were treated with all-trans-retinoic acid (45 mg/m² in 2 divided doses), granulocyte colony-stimulating factor (started at 1 microgram/kg per day), erythropoietin (5,000 IU per day starting on day 2), and vitamin E (400 IU per day). Vitamin E reduced the toxicity and increased the response rate without affecting the performance of all-trans-retinoic acid.¹²⁶

In an observational study involving 1 patient, the patient developed a skin carcinoma in a chest wall scar from having a mastectomy and radiation therapy 17 years earlier. After surgical excision of the carcinoma, she was treated with radiation therapy to the site. She also was given a vasodilator (pentoxifylline 1,200 mg/d) and vitamin E (400 IU per day) in an attempt to reduce the new scar formation. The authors concluded that vitamin E decreased the side effects of radiation, and the skin condition began to improve by the fourth month.¹²⁷

In an observational study of 21 patients with metastatic breast cancer, patients had endomyocardial biopsies and were given alpha-tocopherol orally at 2 g/m² daily starting 7 days before cyclophosphamide, adriamycin, and 5-fluorouracil administration. Vitamin E did not compromise the antitumor activity of the chemotherapy. Fifteen of 21 achieved an objective response—similar to the authors' previous experience. Vitamin E allowed for an additional 100 mg/m² of adriamycin to be given, but the authors stated that vitamin E did not protect the heart.⁴⁵

In a randomized study of 12 patients with metastatic breast cancer, patients were treated with doxorubicin as an intravenous bolus infusion (60 mg/m²), and 6 were randomized to receive 200 mg alpha-tocopherol given intramuscularly 6 hours before infusion and 60 mg nifedipine given orally each day for 2 days before treatment. A higher response rate was achieved and cardiac toxicity was prevented in those who received vitamin E and nifedipine.⁴⁶

In a randomized study of 20 patients with acute myelogenous leukemia, patients were given vitamin E daily and treated with induction chemotherapy (10 patients) and intensive chemotherapy followed by bone marrow transplantation (10 patients). Vitamin E increased treatment response rate and prevented mucositis—an inflammatory response of the oral cavity caused by radiation therapy—especially during induction therapy for acute myelogenous leukemia.¹²⁸

In a randomized study of 18 patients with various cancers, patients received chemotherapy appropriate for their cancer site and were randomized to receive either placebo oil or topical vitamin E (400 IU/cc) to control mucositis. For the 16 patients with head and neck cancer, 5-fluorouracil (1,000 mg/m² as a continuous infusion for 5 days) and cisplatin (100 mg/m² on day 2) were given. For the patient with hepatocellular carcinoma, doxorubicin (45 mg/m² every 3 weeks) was given. The patient with acute myelogenous leukemia (AML) received Ara-C (100 mg/m²/d for 7 days) and doxorubicin (45 mg/m² on days 1-3). Oral mucositis lesions were observed daily before and 5 days after the application of either vitamin E or placebo oil. Vitamin E prevented chemotherapy-induced mucositis. In fact, whereas only 1 of 9 patients receiving placebo achieved complete resolution of their oral lesion, 6 of 9 patients receiving vitamin E achieved complete resolution.¹²⁹

In a randomized study of 16 patients with various cancers, all participants were treated with a regimen containing adriamycin appropriate for the cancer site. Seven were randomized to receive 1,800 IU tocopherol daily starting 24 hours before adriamycin administration and continuing for at least 1 week after adriamycin administration. Vitamin E did not interfere with chemotherapy but also did not protect against cardiac toxicity.⁴⁷

Sixteen evaluable cancer patients in an observational study of 18 patients receiving adriamycin were given dl-alpha-tocopherol acetate (1,600 IU a day) to determine whether vitamin E would protect against alopecia (hair loss), which occurs in virtually all patients receiving adriamycin. Sixty-nine percent of patients given adriamycin and vitamin E did not have alopecia.

Furthermore, a correlation was found between the time vitamin E was taken and the degree of alopecia. Most patients who began taking tocopherol more than 72 hours before chemotherapy treatment did not have alopecia.¹³⁰

SUMMARY

These studies show that vitamin A, beta-carotene, and vitamin E do not interfere with and actually can enhance the killing capabilities of therapeutic modalities for cancer, decrease their side effects, protect normal tissues, and, in some studies, prolong survival. Part 2 will review antioxidant combinations, B vitamins, vitamins D₃ and K₃, and the glutathione-selenium complex. A summary and discussion will then be presented.

REFERENCES

- Jemal A, Murray T, Samuels A, et al. Cancer Statistics, 2005. *CA Cancer J Clin*. 2005;55(1):10-30.
- US Bureau of Vital Statistics, 1900 to present.
- Bailar JC 3rd, Smith EM. Progress against cancer? *N Engl J Med*. 1986;314(19):1226-1232.
- U.S. Department of Health and Human Services, Public Health Service. *The Surgeon General's Report on Nutrition and Health*. Washington, D.C.: US Gov Print Office; 1990.
- National Research Council (U.S.). *Diet and Health: Implications for Reducing Chronic Disease Risk*. Washington, D.C.: National Academy Press; 1989.
- Capizzi RL. Clinical status and optimal use of Amifostine. *Oncology*. 1999;13(1):47-59.
- Bohuslavizki KH, Klutmann S, Brenner W, et al. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. *J Clin Oncol*. 1998;16:3542-3549.
- Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. *J Clin Oncol*. 2000;18(19):3339-3345.
- Coleman CN, Bump EA, Kramer RA. Chemical modifiers of cancer treatment. *J Clin Oncol*. 1988;6(4):709-733.
- Constine LS, Zagars G, Rubin P, Kligerman M. Protection by WR-2721 of human bone marrow function following irradiation. *Int J Radiat Oncol Biol Phys*. 1986;12(8):1505-1508.
- Douay L, Mu C, Giarratana MC, et al. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. *Blood*. 1995;86(7):2849-2855.
- Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. *J Clin Oncol*. 1996;14(7):2101-2112.
- Kligerman MM, Glover DJ, Turrisi AT, et al. Toxicity of WR-2721 administered in single and multiple doses. *Int J Radiat Oncol Biol Phys*. 1984;10(9):1773-1776.
- Santini V, Giles FJ. The potential of amifostine: from cytoprotectant to therapeutic agent. *Haematologica*. 1999;84(11):1035-1042.
- Schein, PS. Results of chemotherapy and radiation therapy protection trials with WR-2721. *Cancer Invest*. 1992;10(1):24-26.
- Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin and vinblastine in metastatic non-small cell lung cancer: a report of high response rates and prolonged survival. *J Clin Oncol*. 1996;14(6):1913-1921.
- Tannehill SP, Mehta MP. Amifostine and radiation therapy: past, present, and future. *Semin Oncol*. 1996;23(4 Suppl 8):69-77.
- Wasserman TH, Brizel DM. The role of amifostine as a radioprotector. *Oncology*. 2001;15(10):1349-1354.
- Carlson, R.W. Reducing the cardiotoxicity of the anthracyclines. *Oncology*. 1992;6(6):95-100,104,107.
- Hellmann K. Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index. *J Clin Oncol*. 1996;14(2):332-333.
- Klein P, Muggia FM. Cytoprotection: shelter from the storm. *Oncologist*. 1999;4(2):112-121.
- Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchini JR, Gams Ra. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. *J Clin Oncol*. 1997;15(4):1333-1340.
- Myers C, Gianni L, Simone CB, Klecker R, Greene R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. *Biochemistry*. 1982;21(8):1707-1712.
- Carmine TC, Evans P, Bruchelt G, Evans R, Handgretinger R, Niethammer D, Halliwell B. Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management. *Cancer Lett*. 1995;94(2):219-226.
- Gordeuk VR, Brittenham GM. Bleomycin-reactive iron in patients with acute non-lymphocytic leukemia. *FEBS Lett*. 1992;308(1):4-6.
- Halliwell B, Aruoma OI, Mufti G, Bomford A. Bleomycin-detectable iron in serum from leukaemic patients before and after chemotherapy. Therapeutic implications for treatment with oxidant-generating drugs. *FEBS Lett*. 1988;241(1-2):202-204.
- Brody JE. In vitamin mania, millions take a gamble on health. *The New York Times*. October 26, 1997; 1, 20, 21 (quoting Larry Norton, MD of Memorial Sloan Kettering, NYC).
- Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. *Oncology*. 1999;13(7):1003-1008.
- Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. *Cancer Res*. 1999;59(18):4555-4558.
- Gottlieb N. Cancer treatment and vitamin C: the debate lingers. *JNCI*. 1999;91(24):2073-2075.
- Brown J, Byers T, Thompson K, Eldridge B, Doyle C, Williams AM. Nutrition during and after cancer treatment: a guide for informed choices by cancer survivors. *CA Cancer J Clin*. 2001;51(3):153-187.
- The American Cancer Society. Selecting which drugs to use for chemotherapy treatments. Available at: http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Selecting_Which_Drugs_to_Use_For_Chemotherapy_Treatments.asp?sitearea=ETO. Accessed November 30, 2006.
- Leeb BF, Witzmann G, Ogris E, et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. *Clin Exp Rheumatol*. 1995;13(4):459-463.
- Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double blind, placebo-controlled trial. *Ann Intern Med*. 1994;121(11):833-841.
- Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. *J Rheumatology*. 1997;24(11):2230-2232.
- Basu TK. Significance of vitamins in cancer. *Oncology*. 1976;33(4):183-187.
- Bhuvaramurthy V, Balasubramanian N, Govindasamy S. Effect of radiotherapy and chemoradiotherapy on the circulating antioxidant system of human uterine cervical carcinoma. *Mol Cell Biochem*. 1996;158(1):17-23.
- Clemens MR, Ladner C, Ehninger G, et al. Plasma vitamin E and beta-carotene concentrations during radiochemotherapy preceding bone marrow transplantation. *Am J Clin Nutr*. 1990;51(2):216-219.
- Clemens MR, Ladner C, Schmidt H, et al. Decreased essential antioxidants and increased lipid hydroperoxides following high-dose radiochemotherapy. *Free Rad Res Commun*. 1989;7(3-6):227-232.
- Clemens MR, Ladner C, Schmidt H, et al. Decrease of alpha-tocopherol and beta-carotene by high-dose radiochemotherapy preceding bone marrow transplantation. *Ann NY Acad Sci*. 1989;570:431-434.
- Clemens MR, Muller-Ladner CI, Gey KF. [Vitamins during high dose chemo- and radiotherapy] [Article in German]. *Z Ernahrungswiss*. 1992;31(2):110-120.
- Clemens MR. [Vitamins and therapy of malignancies] [Article in German]. *Ther Umsch*. 1994;51(7):483-488.
- Drizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. *Postgraduate Med*. 1990;87(1):163-167,170.
- Durken M, Herrnring C, Finckh B, et al. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. *Free Radic Biol Med*. 2000;28(6):887-894.
- Durken M, Agbenu J, Finckh B, et al. Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation. *Bone Marrow Transplant*. 1995;15(5):757-762.
- Erhola M, Kellokumpu-Lehtinen P, Metsa-Ketela T, Alanko K, Nieminen MM. Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients. *Free Radic Biol Med*. 1996;21(3):383-390.
- Erhola M, Nieminen MM, Ojala A, Metsa-Ketela T, Kellokumpu-Lehtinen P, Alho H. Human plasma antioxidant capacity during radiotherapy for lung cancer: a clinical study. *J Exp Clin Cancer Res*. 1998;17(3):325-330.
- Faber M, Coudray C, Hida H, Mousseau M, Favier A. Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study. *Biol Trace Elem Res*. 1995;47(1-3):117-123.
- Faure H, Coudray C, Mousseau M, Ducros V, Douki T, Bianchini F, Cadet J. 5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in adriamycin-treated patients. *Free Radic Biol Med*. 1996;20(7):979-983.
- Henquin N, Havivi E, Reshef A, Barak F, Horn V. Nutritional monitoring and counselling for cancer patients during chemotherapy. *Oncology*. 1989;46(3):173-177.
- Henriksson, Rogo KO, Grankvist K. Interaction between cytostatics and nutrients. *Med Oncol Tumor Pharmacother*. 1991;8(2):79-86.
- Kakar S, Wilson C, Bell J. Plasma and leucocyte ascorbic acid concentration in acute lymphoblastic leukaemia. *Ir J Med Sci*. 1975;144:227-232.
- Ladner C, Ehninger G, Gey KF, Clemens MR. Effect of etoposide (VP-16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen. *Cancer Chemother Pharmacol*. 1989;25(3):210-212.
- Look MP, Musch E. Lipid peroxides in the polychemotherapy of cancer patients. *Chemotherapy*. 1994;40(1):8-15.
- Ohnuma T, Holland JF. Nutritional consequences of cancer chemotherapy and immunotherapy. *Cancer Res*. 1977;37(7 Pt 2):2395-2406.
- Ojiro M, Takenoshita M, Toshinaga T, Shimazu H. [Significance of vitamin K (VK) administration in patients under chemotherapy during postoperative fasting period] [Article in Japanese]. *Nippon Geka Gakkai Zasshi*. 1992;93(1):9-15.
- Potischman N, Byers T, Houghton L, Root M, Nemoto T, Campbell TC. Effects of breast cancer treatments on plasma nutrient levels: implications for epidemiological

- studies. *Cancer Epidemiol Biomarkers Prev.* 1992;1(7):555-559.
58. Sangeetha P, Das UN, Koratkar R, Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy for patients with cancer. *Free Radic Biol Med.* 1990;8(1):15-19.
 59. Schreurs WH, Odink J, Egger RJ, Wedel M, Bruning PF. The influence of radiotherapy and chemotherapy on the vitamin status of cancer patients. *Int J Vitam Nutr Res.* 1985;55(4):425-432.
 60. Senturker S, Karahalil B, Inal M, et al. Oxidative DNA base damage and antioxidant enzyme levels in childhood acute lymphoblastic leukemia. *FEBS Lett.* 1997;416(3):286-290.
 61. Sobol SM, Conoyer JM, Zill R, Thawley SE, Ogura JH. Nutritional concepts in the management of the head and neck cancer patient. II. Management concepts. *Laryngoscope.* 1979;89(6 Pt 1):962-979.
 62. Stahelin HB. Critical reappraisal of vitamins and trace minerals in nutritional support of cancer patients. *Support Care Cancer.* 1993;1(6):295-297.
 63. Subramaniam S, Shyama S, Jagadeesan M, Shyamala Devi CS. Oxidant and antioxidant levels in the erythrocytes of breast cancer patients treated with CMF. *Med Sci Res.* 1993;21(2):79-80.
 64. Wayner DD, Burton GW, Ingold KU, Barclay LR, Locke SJ. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxy radical-trapping antioxidant activity of human blood plasma. *Biochim Biophys Acta.* 1987;924(3):408-419.
 65. Weijl NI, Hopman GD, Wipkink-Bakker A, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. *Ann Oncol.* 1998;9(12):1331-1337.
 66. Yang KC, Li X, and Tsui ZC. The relationship between nutritional antioxidants and serum lipid peroxides in cancer patients. *In Vivo.* 1989;3(3):211-214.
 67. Dorr RT. Cytoprotective agents for anthracyclines. *Semin Oncol.* 1996;23(4 Suppl 8):23-34.
 68. Ciaccio M, Tesoriere L, Pintaudi AM, et al. Vitamin A preserves the cytotoxic activity of adriamycin while counteracting its peroxidative effects in human leukemic cells in vitro. *Biochem Mol Biol Int.* 1994;34(2):329-335.
 69. Ripoll, EA, Rama BN, Webber MM. Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. *J Urol.* 1986;136(2):529-531.
 70. Shimpo K, Nagatsu T, Yamada K, et al. Ascorbic acid and adriamycin toxicity. *Am J Clin Nutr.* 1991;54(6 suppl):1298S-1301S.
 71. Geetha A, Sankar R, Marar T, Devi CS. Alpha-tocopherol reduces doxorubicin-induced toxicity in rats—histological and biochemical evidences. *Indian J Physiol Pharmacol.* 1990;34(2):94-98.
 72. Jotti A, Maiorino M, Paracchini L, Piccinini F, Ursini F. Protective effect of dietary selenium supplementation on delayed cardiotoxicity of adriamycin in rat: is PHGPX but not GPX involved? *Free Radic Biol Med.* 1994;16(2):284-288.
 73. Myers CE, McGuire W, Young R. Adriamycin: amelioration of toxicity by alpha-tocopherol. *Cancer Treat Rep.* 1976;60(7):961-962.
 74. Singal PK, Tong JG. Vitamin E deficiency accentuates adriamycin-induced cardiomyopathy and cell surface changes. *Mol Cell Biochem.* 1988;84(2):163-171.
 75. Siveski-Ilskovic N, Kaul N, Singal PK. Probuco promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. *Circulation.* 1994;89(6):2829-2835.
 76. Legha SS, Wang YM, Mackay B, et al. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. *Ann N Y Acad Sci.* 1982;393:411-418.
 77. Lenzhofer R, Ganzinger U, Rameis H, Moser K. Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment. *J Cancer Res Clin Oncol.* 1983;106(2):143-147.
 78. Weitzman SA, Lorell E, Carey RW, Kaufman S, Stoszel TP. Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity. *Curr Ther Res.* 1980;28:682-686.
 79. Anderson D, Basaran N, Blowers SD, Edwards AJ. The effect of antioxidants on bleomycin treatment in in vitro and in vivo genotoxicity assays. *Mutat Res.* 1995;329(1):37-47.
 80. Bianchi L, Tateo F, Pizzala R. Carotenoids reduce the chromosomal damage induced by bleomycin in human cultured lymphocytes. *Anticancer Res.* 1993;13(4):1007-1010.
 81. Bump EA, Braunhut SJ, Palayoor ST, et al. Novel concepts in modification of radiation sensitivity. *Int J Radiat Oncol Biol Phys.* 1994;29(2):249-253.
 82. Chiang CD, Song EJ, Yang VC, Chao CC. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small cell lung-cancer cells. *Biochem J.* 1994;301(Pt 3):759-764.
 83. Harapanhalli RS, Narra VR, Yaghmai V, et al. Vitamins as radioprotectors in vivo. II. Protection by vitamin A and soybean oil against radiation damage caused by internal radionuclides. *Radiat Res.* 1994;139(1):115-122.
 84. Komiyama S, Kudoh S, Yanagita T, Kuwano M. Synergistic combination of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors—antitumor combination therapy with vitamin A. *Auris Nasus Larynx.* 1985;12(Suppl 2):S239-S243.
 85. Prasad KN, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson WA. Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. *Nutr Cancer.* 1994;22(3):233-245.
 86. Salvadori DM, Ribeiro LR, Natarajan AT. Effect of beta-carotene on clastogenic effects of mitomycin C, methyl methanesulphonate and bleomycin in Chinese hamster ovary cells. *Mutagenesis.* 1994;9(1):53-57.
 87. Sweetman SF, Strain JJ, McKelvey-Martin VJ. Effect of antioxidant vitamin supplementation on DNA damage and repair in human lymphoblastoid cells. *Nutr Cancer.* 1997;27(2):122-130.

88. Vadgama JV, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. *Anticancer Res.* 2000;20(3A):1391-1414.
89. Appenroth D, Winnefeld K. Role of glutathione for cisplatin nephrotoxicity in young and adult rats. *Ren Fail.* 1993;15(2):135-139.
90. Baldew GS, Mol JG, de Kanter FJ, van Baar B, de Goeij JJ, Vermeulen NP. The mechanism of interaction between cisplatin and selenite. *Biochem Pharmacol.* 1991;41(10):1429-1437.
91. Baraboi VA, Oleinik SA, Blium IA, Khmelevskii IuV. [Pro-oxidant and antioxidant homeostasis in guinea pigs following fractionated x-ray irradiation at low doses and the correction of disorders with an antioxidant complex] [Article in Russian]. *Radiats Biol Radioecol.* 1994;34(2):240-246.
92. Ben-Amotz A, Rachmilevich B, Greenberg S, Sela M, Weshler Z. Natural beta-carotene and whole body irradiation in rats. *Radiat Environ Biophys.* 1996;35(4):285-288.
93. Crary EJ, McCarty MF. Potential clinical applications for high-dose nutritional antioxidants. *Med Hypotheses.* 1984;13(1):77-98.
94. El-Nahas SM, Mattar FE, Mohamed AA. Radioprotective effect of vitamins C and E. *Mutat Res.* 1993;301(2):143-147.
95. Kagerud, A, Peterson HI. Effect of tocopherol in irradiation of artificially hypoxic rat tumours. Second Rome International Symposium: Biological Bases and Clinical Implications. September 21, 1980; 3-9.
96. Kilinc C, Ozcan O, Karaoz E, Sunguroglu K, Kutluay T, Karaca L. Vitamin E reduces bleomycin-induced lung fibrosis in mice: biochemical and morphological studies. *J Basic Clin Physiol Pharmacol.* 1993;4(3):249-269.
97. Nagai Y, Horie T, Awazu S. Vitamin A, a useful biochemical modulator capable of preventing intestinal damage during methotrexate treatment. *Pharmacol Toxicol.* 1993;73(2):69-74.
98. Nakamura T, Pinnell SR, Darr D, et al. Vitamin C abrogates the deleterious effects of UVB radiation on cutaneous immunity by a mechanism that does not depend on TNF-alpha. *J Invest Dermatol.* 1997;109(1):20-24.
99. Odagiri Y, Karube T, Katayama H, Takemoto K. Modification of the clastogenic activity of X-ray and 6-mercaptopurine in mice by prefeeding with vitamins C and E. *J Nutr.* 1992;122(7):1553-1558.
100. Okunieff, P. Interactions between ascorbic acid and the radiation of bone marrow, skin, and tumor. *Am J Clin Nutr.* 1991;54(6 Suppl):1281S-1283S.
101. Perez JE, Macchiavelli M, Leone BA, et al. High-dose alpha-tocopherol as a preventive of doxorubicin-induced alopecia. *Cancer Treatment Rep.* 1986;70(10):1213-1214.
102. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. *Pharmacol Toxicol.* 1995;76(6):386-394.
103. Riabchenko NI, Ivannik BP, Khorokhorina VA, Riabchenko VI, Sin'kova RV, Groshveva IP, Dzikovskaia. [The molecular, cellular and systemic mechanisms of the radioprotective action of multivitamin antioxidant complexes] [Article in Russian]. *Radiats Biol Radioecol.* 1996;36(6):895-899.
104. Satoh M, Naganuma A, Imura N. Effect of co-administration of selenite on the toxicity and anti-tumor activity of cisplatin given repeatedly to mice. *Cancer Chemotherapy Pharmacol.* 1992;30:439-443.
105. Sminia P, van der Kracht AH, Frederiks WM, Jansen W. Hyperthermia, radiation carcinogenesis and the protective potential of vitamin A and N-acetylcysteine. *J Cancer Res Clin Oncol.* 1996;122(6):343-350.
106. Srinivasan V, Weiss JF. Radioprotection by vitamin E: injectable vitamin E administered alone or with WR-3689 enhances the survival of irradiated mice. *Int J Radiat Oncol Biol Phys.* 1992;23(4):841-845.
107. Vinitha R, Thangaraju M, Sachdanandam P. Effect of administering cyclophosphamide and vitamin E on the levels of tumor-marker enzymes in rats with experimentally induced fibrosarcoma. *Jpn J Med Sci Biol.* 1995;48(3):145-156.
108. Wiseman JS, Senagore AJ, Chaudry IH. Methods to prevent colonic injury in pelvic radiation. *Dis Colon Rectum.* 1994;37(11):1090-1094.
109. Zidenberg-Cherr S, Keen CL. Influence of dietary manganese and vitamin E on adriamycin toxicity in mice. *Toxicol Lett.* 1986;30(1):79-87.
110. Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. *Chem Biol Interact.* 1989;70(1-2):89-101.
111. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. *N Engl J Med.* 2000;342(25):1878-1886.
112. Ottenbacher K. Impact of random assignment on study outcome: an empirical examination. *Control Clin Trials.* 1992;13(1):50-61.
113. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med.* 2000;342(25):1887-1892.
114. Israel L, Hajji O, Grefft-Alami A, et al. [Vitamin A augmentation of the effects of chemotherapy in metastatic breast cancers after menopause. Randomized trial in 100 patients] [Article in French]. *Ann Med Interne.* 1985;136(7):551-554.
115. Komiyaama S, Kudoh S, Yanagita T, Kuwano M. Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors—antitumor combination therapy with vitamin A. *Auris Nasus Larynx.* 1985;12(Suppl 2):S239-S243.
116. Meyskens FL, Kopecky KJ. Phase III randomized trial of the treatment of chronic stage CML with pulse, intermittent busulfan therapy (SWOG 7984): improved survival with the addition of oral vitamin A (50,000 IU/day). Seventh International Conference on the Adjuvant Therapy of Cancer. Tucson, Ariz. March 10-13, 1993: 35.
117. Recchia F, de Filippis S, Rea S, Corrao G, Frati L. Cisplatin, vindesine, 5-fluorouracil, beta-interferon and retinyl palmitate in advanced non-small cell lung cancer. A phase II study. *Proc Annu Meet Am Soc Clin Oncol.* 1993;12:A1144.
118. Recchia F, Lelli S, Di Matteo G, Rea S, Frati L. [5FU, cisplatin and retinyl palmitate in the management of advanced cancer of the oral cavity. Phase II study] [Article in Italian]. *Clin Ter.* 1993;142(5):403-409.
119. Recchia F, Rea S, Pompili P, et al. Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. *Clin Ter.* 1995;146(10):603-610.
120. Recchia F, Serafini F, Rea S, Frati L. Phase II study of 5-fluorouracil, folinic acid, epirubicin, mitomycin-C, beta-interferon and retinyl palmitate in patients with unresectable pancreatic carcinoma. *Proc Annu Meet Am Assoc Cancer Res.* 1992;33:A1296.
121. Recchia F, Sica G, de Filippis S, et al. Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer: a phase II study. *J Interferon Cytokine Res.* 1995;15(7):605-610.
122. Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. *Br J Cancer.* 1988;57(4):416-417.
123. Santamaria L, Bianchi-Santamaria A, dell'Orti M. Carotenoids in cancer, mastalgia, and AIDS: prevention and treatment—an overview. *J Environ Pathol Toxicol Oncol.* 1996;15(2-4):89-95.
124. Besa EC, Abraham IL, Bartholomew MJ, Hyzinski M, Nowell PC. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. *Am J Med.* 1990;89(6):739-747.
125. Dimery I, Shirinian M, Heyne K, et al. Reduction in toxicity of high dose 13-cis-retinoic acid with alpha-tocopherol. *Proc Annu Meet Am Soc Clin Oncol.* 1992;11:A399.
126. Ganser A, Maurer A, Contzen C, et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. *Ann Hematol.* 1996;72(4):237-244.
127. Gottlober P, Krahn G, Korting HC, Stock W, Peter RU. [The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report] [Article in German]. *Strahlenther Onkol.* 1996;172(1):34-38.
128. Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq, Dreyfus F. [Treatment of mucositis with vitamin E during administration of neutropenic antineoplastic agents] [Article in French]. *Ann Med Interne.* 1994;145(6):405-408.
129. Wadleigh RG, Redman RS, Graham ML, Krasnow SH, Anderson A, Cohen MH. Vitamin E in the treatment of chemotherapy induced mucositis. *Am J Med.* 1992;92(5):481-484.
130. Wood LA. Possible prevention of adriamycin-induced alopecia by tocopherol. *N Engl J Med.* 1985;312(16):1060.